

# David Matthews

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/719631/publications.pdf>

Version: 2024-02-01

124  
papers

72,884  
citations

29994

54  
h-index

19690

117  
g-index

130  
all docs

130  
docs citations

130  
times ranked

55985  
citing authors

#	ARTICLE	IF	CITATIONS
1	Homeostasis model assessment: insulin resistance and $\beta$ -cell function from fasting plasma glucose and insulin concentrations in man. <i>Diabetologia</i> , 1985, 28, 412-419.	2.9	27,582
2	Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. <i>BMJ: British Medical Journal</i> , 2000, 321, 405-412.	2.4	7,060
3	10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 359, 1577-1589.	13.9	6,543
4	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 644-657.	13.9	5,629
5	Use and Abuse of HOMA Modeling. <i>Diabetes Care</i> , 2004, 27, 1487-1495.	4.3	4,019
6	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. <i>Diabetes Care</i> , 2012, 35, 1364-1379.	4.3	3,077
7	Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2015, 38, 140-149.	4.3	2,326
8	Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program. <i>Diabetes Care</i> , 1998, 21, 2191-2192.	4.3	1,745
9	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. <i>BMJ: British Medical Journal</i> , 2000, 321, 412-419.	2.4	1,737
10	Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2012, 55, 1577-1596.	2.9	1,718
11	UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. <i>Diabetologia</i> , 2001, 44, 156-163.	2.9	840
12	Sodium-glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2013, 159, 262.	2.0	749
13	Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 359, 1565-1576.	13.9	674
14	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2015, 58, 429-442.	2.9	598
15	Grand challenges in chronic non-communicable diseases. <i>Nature</i> , 2007, 450, 494-496.	13.7	562
16	Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2014, 371, 1392-1406.	13.9	520
17	Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 691-704.	5.5	460
18	Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. <i>Circulation</i> , 2018, 137, 323-334.	1.6	393

#	ARTICLE	IF	CITATIONS
19	Risks of Progression of Retinopathy and Vision Loss Related to Tight Blood Pressure Control in Type 2 Diabetes Mellitus. JAMA Ophthalmology, 2004, 122, 1631.	2.6	377
20	Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ: British Medical Journal, 2012, 344, e1369-e1369.	2.4	356
21	Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax, 2007, 62, 969-974.	2.7	355
22	UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. , 1998, 15, 297-303.		290
23	Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)â€”A randomized placebo-controlled trial. American Heart Journal, 2013, 166, 217-223.e11.	1.2	290
24	Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet, The, 2019, 394, 1519-1529.	6.3	210
25	Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care, 2016, 39, 694-700.	4.3	184
26	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. Annals of Internal Medicine, 2020, 173, 278-286.	2.0	182
27	Vildagliptin addâ€”on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2â€”year study. Diabetes, Obesity and Metabolism, 2010, 12, 780-789.	2.2	178
28	Semaglutide, reduction in glycosylated haemoglobin and the risk of diabetic retinopathy. Diabetes, Obesity and Metabolism, 2018, 20, 889-897.	2.2	173
29	Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia, 2005, 48, 1093-1104.	2.9	160
30	Control of pulsatile insulin secretion in man. Diabetologia, 1983, 24, 231-7.	2.9	157
31	Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metabolism Research and Reviews, 2005, 21, 167-174.	1.7	153
32	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Studyâ€”Renal (<sc>CANVASâ€”R</sc>): A randomized, placeboâ€”controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 387-393.	2.2	139
33	Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. Diabetes, Obesity and Metabolism, 2019, 21, 454-466.	2.2	129
34	Microaneurysms in the development of diabetic retinopathy (UKPDS 42). Diabetologia, 1999, 42, 1107-1112.	2.9	124
35	Longâ€”term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2â€”year results from the <sc>LEAD</sc>â€”2 study. Diabetes, Obesity and Metabolism, 2013, 15, 204-212.	2.2	123
36	Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2591-2593.	1.6	121

#	ARTICLE	IF	CITATIONS
37	Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. <i>Diabetologia</i> , 2020, 63, 1440-1452.	2.9	121
38	An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. <i>Diabetic Medicine</i> , 2004, 21, 568-576.	1.2	108
39	Prevalence of overweight and obesity in Sri Lankan adults. <i>Obesity Reviews</i> , 2010, 11, 751-756.	3.1	99
40	Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. <i>Diabetologia</i> , 2019, 62, 926-938.	2.9	94
41	Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2229-2242.	3.0	93
42	Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. <i>JACC: Heart Failure</i> , 2020, 8, 57-66.	1.9	93
43	Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. <i>Diabetologia</i> , 2022, 65, 1251-1261.	2.9	93
44	Expansion of the Homeostasis Model Assessment of $\beta$ -Cell Function and Insulin Resistance to Enable Clinical Trial Outcome Modeling Through the Interactive Adjustment of Physiology and Treatment Effects: iHOMA2. <i>Diabetes Care</i> , 2013, 36, 2324-2330.	4.3	92
45	Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 926-935.	2.2	89
46	The hospital and home use of a 30-second hand-held blood ketone meter: guidelines for clinical practice. <i>Diabetic Medicine</i> , 2001, 18, 640-645.	1.2	88
47	Recent advances in the monitoring and management of diabetic ketoacidosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2004, 97, 773-780.	0.2	88
48	Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2116-2124.	2.2	79
49	Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2005, 70, 53-62.	1.1	77
50	Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy. <i>Diabetes Care</i> , 2010, 33, 730-732.	4.3	76
51	Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 82-91.	2.2	74
52	Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. <i>Cardiovascular Diabetology</i> , 2016, 15, 129.	2.7	73
53	Acute effect of fructose on postprandial lipaemia in diabetic and non-diabetic subjects. <i>British Journal of Nutrition</i> , 1998, 80, 169-175.	1.2	72
54	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2255-2263.	2.2	71

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of once-a-week glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1065-1074.	2.2	61
56	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108737.	1.1	61
57	Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. <i>Diabetologia</i> , 2019, 62, 1854-1867.	2.9	58
58	Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 335-345.	2.2	54
59	Remote assessment of diabetic foot ulcers using a novel wound imaging system. <i>Wound Repair and Regeneration</i> , 2011, 19, 25-30.	1.5	52
60	Canagliflozin and Stroke in Type 2 Diabetes Mellitus. <i>Stroke</i> , 2019, 50, 396-404.	1.0	51
61	N of 1 trials in diabetes: making individual therapeutic decisions. <i>Diabetologia</i> , 2008, 51, 921-925.	2.9	46
62	Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON. <i>Diabetes Care</i> , 2018, 41, 163-170.	4.3	46
63	Coefficient of failure: a methodology for examining longitudinal $\beta$ -cell function in Type 2 diabetes. <i>Diabetic Medicine</i> , 2002, 19, 465-469.	1.2	44
64	Banting Memorial Lecture 2010. Type 2 diabetes as an "infectious" disease: is this the Black Death of the 21st century?. <i>Diabetic Medicine</i> , 2011, 28, 2-9.	1.2	43
65	The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 1-14.	1.1	43
66	Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 216-218.	0.9	40
67	Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. <i>American Journal of Kidney Diseases</i> , 2021, 77, 23-34.e1.	2.1	38
68	Insulin resistance and $\beta$ -cell function - a clinical perspective. <i>Diabetes, Obesity and Metabolism</i> , 2001, 3, 28-33.	2.2	36
69	Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. <i>Diabetes Therapy</i> , 2015, 6, 289-302.	1.2	36
70	Children with Type 2 Diabetes: The Risks of Complications. <i>Hormone Research in Paediatrics</i> , 2002, 57, 34-39.	0.8	35
71	Community Interventions for Health (CIH): A novel approach to tackling the worldwide epidemic of chronic diseases. <i>CVD Prevention and Control</i> , 2011, 6, 47.	0.7	35
72	Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy: the VERIFY trial: a randomized double-blind trial. <i>Diabetic Medicine</i> , 2014, 31, 1178-1184.	1.2	35

#	ARTICLE	IF	CITATIONS
73	The diabetes epidemic in Sri Lanka â€” a growing problem. <i>Ceylon Medical Journal</i> , 2009, 51, 26.	0.1	35
74	Glucagonâ€like peptideâ€1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and metaâ€analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 188-193.	2.2	33
75	Unbiased and Flexible Iterative Computer Program to Achieve Glucose Clamping. <i>Diabetes Care</i> , 1989, 12, 156-159.	4.3	28
76	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Spectrum</i> , 2012, 25, 154-171.	0.4	28
77	Response to Comments on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015;38:140â€149. <i>Diabetes Care</i> , 2015, 38, e128-e129.	4.3	25
78	Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. <i>Diabetologia</i> , 2021, 64, 2012-2025.	2.9	24
79	Prevalence, patterns, and associations of dyslipidemia among Sri Lankan adultsâ€”Sri Lanka Diabetes and Cardiovascular Study in 2005â€2006. <i>Journal of Clinical Lipidology</i> , 2018, 12, 447-454.	0.6	23
80	Prediction of 10â€year vascular risk in patients with diabetes: the <sc>ADâ€ON</sc> risk score. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 289-294.	2.2	21
81	Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 843-851.	0.9	19
82	Sotagliflozin for patients with type <sc>2</sc> diabetes: A systematic review and metaâ€analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 106-114.	2.2	19
83	Ultraâ€rapidâ€acting insulins for adults with diabetes: A systematic review and metaâ€analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2395-2401.	2.2	18
84	Successful Up-Scaled Population Interventions to Reduce Risk Factors for Non-Communicable Disease in Adults: Results from the International Community Interventions for Health (CIH) Project in China, India and Mexico. <i>PLoS ONE</i> , 2015, 10, e0120941.	1.1	17
85	Comparative efficacy and safety of glucoseâ€lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network metaâ€analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 822-831.	2.2	17
86	Evaluation of physical activity among adults with diabetes mellitus from Sri Lanka. <i>International Archive of Medicine</i> , 2014, 7, 15.	1.2	16
87	Plasma glucose in screening for diabetes and pre-diabetes: how much is too much? Analysis of fasting plasma glucose and oral glucose tolerance test in Sri Lankans. <i>BMC Endocrine Disorders</i> , 2019, 19, 11.	0.9	15
88	The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm. <i>Diabetes Therapy</i> , 2019, 10, 1-13.	1.2	15
89	Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Typeâˆ2 Diabetes. <i>Diabetes Therapy</i> , 2020, 11, 2465-2476.	1.2	15
90	Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 530-539.	2.2	14

#	ARTICLE	IF	CITATIONS
91	Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: A subanalysis of the <sc>VERIFY</sc> study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 245-251.	2.2	13
92	Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial. <i>Cardiovascular Research</i> , 2022, 118, 1103-1114.	1.8	13
93	Development and validation of a Diabetes Risk Score for screening undiagnosed diabetes in Sri Lanka (SLDRISK). <i>BMC Endocrine Disorders</i> , 2016, 16, 42.	0.9	12
94	Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin+metformin combination in newly diagnosed Type 2 diabetes. <i>Diabetic Medicine</i> , 2019, 36, 505-513.	1.2	11
95	Fenofibrate and statin therapy, compared with placebo and statin, slows the development of retinopathy in type 2 diabetes patients of 10 years duration: the ACCORD study. <i>Evidence-Based Medicine</i> , 2011, 16, 45-46.	0.6	9
96	The UK Diabetes Research Network-an opportunity and a challenge. <i>Diabetic Medicine</i> , 2007, 24, 7-9.	1.2	8
97	Evaluation of Common Type 2 Diabetes Risk Variants in a South Asian Population of Sri Lankan Descent. <i>PLoS ONE</i> , 2014, 9, e98608.	1.1	8
98	A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2240-2247.	2.2	8
99	ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter] and Ceriello A, Gallo M, Gentile S et al [letter]. <i>Diabetologia</i> , 2012, 55, 2856-2857.	2.9	6
100	Tobacco Smoking Among School Children in Colombo District, Sri Lanka. <i>Asia-Pacific Journal of Public Health</i> , 2015, 27, NP278-NP287.	0.4	6
101	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. <i>International Journal of Cardiology</i> , 2021, 324, 165-172.	0.8	6
102	Reasons for hospitalizations in patients with type 2 diabetes in the <sc>CANVAS</sc> programme: A secondary analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2707-2715.	2.2	6
103	Insulin resistance and beta-cell function—a clinical perspective. <i>Diabetes, Obesity and Metabolism</i> , 2001, 3 Suppl 1, S28-33.	2.2	6
104	Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the <sc>CANVAS</sc> Program. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2199-2203.	2.2	5
105	Impending type 2 diabetes. <i>Lancet, The</i> , 2009, 373, 2178-2179.	6.3	4
106	Assessment of the effects of insulin secretagogues in humans. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 271-283.	2.2	3
107	Review: Sulphonylureas and the rise and fall of beta-cell function. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, 192-196.	0.6	3
108	Methodology for Quantifying Fasting Glucose Homeostasis in Type 2 Diabetes: Observed Variability and Lability. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 640-645.	1.3	3

#	ARTICLE	IF	CITATIONS
109	Insulin resistance and beta-cell function - a clinical perspective. <i>Diabetes, Obesity and Metabolism</i> , 2001, 3 Suppl 1, 28-33.	2.2	3
110	Higher body mass index is associated with irregular and suppressed insulin pulsatility. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 603-604.	2.2	2
111	Community Interventions for Health can support clinicians in advising patients to reduce tobacco use, improve dietary intake and increase physical activity. <i>Journal of Clinical Nursing</i> , 2016, 25, 3167-3175.	1.4	2
112	Among young Sri Lankan patients with diabetes, how do lipid profiles differ between those with and without metabolic syndrome?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 3057-3063.	1.8	2
113	Exploring pain interference with motor skill learning in humans: a protocol for a systematic review. <i>BMJ Open</i> , 2021, 11, e045841.	0.8	2
114	ADVANCE. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 3-4.	2.2	1
115	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2021, 174, 141.	2.0	1
116	An assessment of low carbohydrate or low fat diets for weight loss at two year's follow-up. <i>Diabetic Medicine</i> , 2009, 27, 363.	1.2	1
117	Dietary advice? Authors' response and erratum for "Effects of three months' diet after diagnosis of type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45)". <i>Diabetic Medicine</i> , 2001, 18, 251-251.	1.2	0
118	Chris Feudtner, <i>Bittersweet: diabetes, insulin and the transformation of illness</i> , Studies in Social Medicine, Chapel Hill and London, University of North Carolina Press, 2003, pp. xxii, 290, illus., £22.95, US\$29.95 (hardback 0-8078-2791-6).. <i>Medical History</i> , 2005, 49, 117-118.	0.1	0
119	Pioglitazone/Metformin. <i>Drugs</i> , 2006, 66, 1878-1880.	4.9	0
120	Banting Memorial Lecture: reply from Matthews and Matthews. Type 2 diabetes as an "infectious" disease: is this the Black Death of the 21st century?. <i>Diabetic Medicine</i> , 2011, 28, 880-880.	1.2	0
121	NIHR Diabetes Research Network: the gold standard for clinical trials?. <i>Practical Diabetes</i> , 2012, 29, 317-319.	0.1	0
122	NIHR Diabetes Research Network: recruitment, recruitment, recruitment. <i>Practical Diabetes</i> , 2012, 29, 369-370.	0.1	0
123	Junior hospital doctors "time to rethink the terminology. <i>Lancet, The</i> , 2017, 390, 2033-2034.	6.3	0
124	Do clinical research networks work? The NIHR diabetes research network after 6 years. <i>Clinical Investigation</i> , 2012, 2, 971-974.	0.0	0